William Dalton, Ph.D., M.D., Moffitt Cancer Center
William (Bill) S. Dalton is President, Chief Executive Officer and Center Director of Moffitt Cancer Center and Research Institute, an NCI-Designated Comprehensive Cancer Center, and serves as Board Chairman of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. A nationally renowned cancer researcher, physician and health policy expert, Dr. Dalton has dedicated his career to the study and development of the most effective approaches to cancer research and care.
Dr. Dalton currently serves as the President-Elect of the Association of American Cancer Institutes and is Chair of the Science Policy & Legislative Affairs Committee of the American Association for Cancer Research. In addition, Dr. Dalton served on the National Cancer Institute (NCI) Board of Scientific Advisors as well as multiple scientific advisory boards at cancer centers and research foundations across the U.S.
In addition to his basic and translational research interests in molecular mechanisms of drug resistance and new drug discovery, in which he has been funded continuously by the NIH/NCI for over 25 years and holds several patents, Dr. Dalton is also interested in the development of personalized cancer care and patient-centered outcomes research. Moffitt’s Total Cancer CareTM is an approach to enhancing access to evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care is one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated for use in development of personalized medicine.
Dr. Dalton has authored or co-authored numerous articles in journals such as Cancer Research, Blood, Immunity, and the Journal of Biochemistry. He serves, or has served, on the editorial boards of Clinical Cancer Research, Molecular Cancer Therapeutics, Archives of Internal Medicine, Leukemia, Cancer Research, and Investigational New Drugs.
Dr. Dalton received his Ph.D. in toxicology and medical life sciences and his M.D. degree from Indiana University. He completed his internship in Internal Medicine at Indiana University, his residency in Medicine at the University of Arizona in Tucson and his fellowships in Oncology and Clinical Pharmacology at the University of Arizona. He is board certified in Internal Medicine and Medical Oncology and is an expert in Multiple Myeloma. Prior to accepting the position as CEO/Center Director at Moffitt, Dr. Dalton was the Dean of the College of Medicine at the University of Arizona.